FDA Approves Takeda’s Orzeyful, First Medicine to Target the Root Cause of Narcolepsy Type 1
The FDA approved Takeda’s Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R)-selective agonist, for narcolepsy type 1 in adults. Takeda and multiple independent outlets describe it as the first medicine approved to address the…
